Provided by Tiger Trade Technology Pte. Ltd.

HANSOH PHARMA

32.180
-1.740-5.13%
Volume:12.23M
Turnover:402.68M
Market Cap:195.14B
PE:29.56
High:34.560
Open:34.040
Low:32.120
Close:33.920
52wk High:43.587
52wk Low:27.658
Shares:6.06B
HK Float Shares:6.06B
Volume Ratio:1.50
T/O Rate:0.20%
Dividend:0.49
Dividend Rate:1.51%
EPS(LYR):1.089
ROE:19.40%
ROA:9.08%
PB:4.41
PE(LYR):29.56
PS:10.48

Loading ...

Hansoh Pharmaceutical Group Stock Rises 6.4% in Hong Kong

Dow Jones
·
Jul 02

Movement Alert|Hansoh Pharmaceutical Rises 6.01% in Regular Trading, Pemosatide Injection Approval Coupled with Pharma Sector Rally

Market Focus
·
Jul 02

Hansoh Pharmaceutical Group Stock Falls 2.3% in Hong Kong

Dow Jones
·
Jun 30

Movement Alert|Hansoh Pharmaceutical Falls 3.03% in Regular Trading, Pharmaceutical Sector Under Broad Selling Pressure

Market Focus
·
Jun 30

Hansoh Pharmaceutical Group Stock Rises 5.8% in Hong Kong

Dow Jones
·
Jun 29

Movement Alert|Hansoh Pharmaceutical Rises 4.88% in Regular Trading, Pharma Sector Rally Combines with Dense Pipeline Catalysts

Market Focus
·
Jun 29

Hansoh Pharma Shareholders Approved 2026 Share Scheme at AGM

Reuters
·
Jun 26

Hansoh Pharmaceutical Group Stock Slides 1.3% in Hong Kong

Dow Jones
·
Jun 24

Movement Alert|Hansoh Pharmaceutical Rises 3.18% in Regular Trading, Receives Inaugural Buy Rating from Guosheng Securities

Market Focus
·
Jun 24

Hansoh Pharmaceutical Group (SEHK:3692) Stock Could Be Below Fair Value After Hang Seng Index Inclusion

Simply Wall St.
·
Jun 21

Hansoh Pharma releases in vitro study data on HS-20094 dual-biased GLP-1/GIP agonist at ENDO 2026

Reuters
·
Jun 16

Hansoh Pharmaceutical Group Stock Rallies 2.6% in Hong Kong

Dow Jones
·
Jun 12

Hansoh Pharma posts 80% MMR at week 48 in phase 1b HS-10382 plus flumatinib trial for newly diagnosed CML-CP

Reuters
·
Jun 12

Hansoh Pharmaceutical Group (SEHK:3692) Valuation Check After Hang Seng China Enterprises Index Inclusion

Simply Wall St.
·
Jun 11

Hansoh Pharma Appoints Guo Ying as Joint Company Secretary Following Zhong Shengli’s Resignation

Bulletin Express
·
Jun 10

Hansoh Pharma’s NDA for HS-10568 Injection Accepted by China’s NMPA

Bulletin Express
·
Jun 10

HANSOH PHARMA Receives NMPA Acceptance for New Drug Application of HS-10568 Injection

Stock News
·
Jun 10

Hansoh Pharma says China regulator accepts NDA for HS-10568 injection in kidney disease complication

Reuters
·
Jun 10

Hansoh Pharmaceutical - Nda for Hs-10,568 Injection Accepted by Nmpa of China for Shpt in Adult Ckd Patients

THOMSON REUTERS
·
Jun 10

HANSOH PHARMA Announces Appointment of Guo Ying as Joint Company Secretary

Stock News
·
Jun 10